BELTSVILLE, Md., May 13, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the closing of its initial public offering of 5,750,000 shares of its common stock at a public offering price of $15.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 750,000 shares of common stock. Including the option exercise, the gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were $86.25 million. All of the shares in the offering were offered by NextCure. NextCure’s common stock is listed on The Nasdaq Global Select Market under the ticker symbol “NXTC.”
Morgan Stanley, BofA Merrill Lynch and Piper Jaffray & Co. acted as joint book-running managers of the offering.
About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. www.nextcure.com
